Description

Description

Diajard-L 5/10mg is a prescription medicine manufactured by Highnoon Laboratories, combining two active ingredients, Empagliflozin and Linagliptin, in a single tablet. This fixed-dose combination brings together two distinct mechanisms of blood sugar control, offering a convenient treatment option for adults with type 2 diabetes mellitus whose condition requires more than one approach to management. Empagliflozin belongs to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class, working by reducing glucose reabsorption in the kidneys and promoting its removal through urine. Linagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, working by helping the body produce more insulin when blood sugar is elevated while also reducing the amount of glucose released by the liver. Together, these two mechanisms complement one another, offering blood sugar support through kidney-based glucose removal alongside improved insulin regulation. Each pack of Diajard-L 5/10mg contains 14 tablets, produced under the quality standards upheld by Highnoon Laboratories.

Ingredients

Diajard-L 5/10mg contains two active ingredients: Empagliflozin at a strength of 5 milligrams and Linagliptin at a strength of 10 milligrams per tablet. In addition to these active components, the formulation includes standard inactive excipients such as binding agents, fillers, and film-coating materials, which support the tablet’s physical integrity, appearance, and consistent behavior after ingestion. These excipients do not contribute to the therapeutic effect but are necessary for proper tablet formulation and stability.

Dosage Form

Diajard-L is available as an oral film-coated tablet. Each pack contains 14 tablets, providing a convenient supply for patients following a regular combination treatment schedule as directed by their physician. Being an oral solid dosage form, it can be swallowed directly with water without requiring special preparation.

Uses

Diajard-L 5/10mg is used to help improve blood sugar control in adults with type 2 diabetes mellitus, particularly in cases where treatment with a single medicine has not achieved adequate control, or where a physician determines that combination therapy involving both an SGLT2 inhibitor and a DPP-4 inhibitor is appropriate. It is typically used alongside dietary changes and regular physical activity as part of an overall diabetes management plan. This medicine is not intended for individuals with type 1 diabetes or for the management of diabetic ketoacidosis. The suitability of this combination for any individual patient should always be assessed by a qualified healthcare provider.

How to Use

Diajard-L should be taken exactly as prescribed by a physician, typically once daily in the morning, with or without food. The tablet should be swallowed whole with a glass of water and should not be crushed or chewed. Consistency in timing is generally encouraged to help maintain steady blood sugar control throughout the day. Patients should continue following any dietary or lifestyle guidance given by their doctor and must not adjust the dosage independently. Regular monitoring of blood sugar levels and kidney function is often recommended while using this combination medicine.

Side Effects

Diajard-L may cause side effects in some individuals, though not everyone experiences them. Commonly reported effects include urinary tract infections, genital yeast infections, and increased urination associated with the Empagliflozin component, along with effects linked to Linagliptin such as mild headache, upper respiratory symptoms, or joint discomfort. Some patients may also experience mild dizziness or symptoms related to dehydration. Rare but more serious effects can include signs of pancreatitis, such as persistent abdominal pain, or ketoacidosis with normal blood sugar readings, presenting as nausea, vomiting, or unusual fatigue, both of which require immediate medical attention. Patients with a history of kidney problems, pancreatitis, dehydration, or recurrent urinary infections should discuss these concerns with their doctor before starting treatment.

Pregnancy & Breastfeeding

The use of Diajard-L during pregnancy or breastfeeding should only take place under the specific direction of a qualified healthcare provider, as its suitability in these situations depends on individual clinical circumstances. Women who are pregnant, planning pregnancy, or breastfeeding should discuss their situation with their doctor before starting or continuing this combination medicine.

Storage Instructions

Diajard-L tablets should be stored in a cool, dry place away from direct sunlight and moisture, at the room temperature indicated on the packaging. Tablets should remain in their original blister pack until use to help protect them from humidity and light exposure. Keep out of reach of children and pets, and avoid storing in areas prone to temperature changes, such as bathrooms or vehicles.

FAQS

Q: Why does Diajard-L combine two different classes of diabetes medicine?
Combining Empagliflozin and Linagliptin allows two different mechanisms, kidney-based glucose removal and improved insulin regulation, to work together for more comprehensive blood sugar support.

Q: Can Diajard-L be taken with food?
Yes, it can be taken with or without food, though maintaining a consistent daily timing is generally encouraged.

Q: Can Diajard-L replace insulin therapy?
No, it works differently from insulin and is not a substitute for insulin therapy in patients who require it.

Q: What should I do if I miss a dose of Diajard-L?
A missed dose should be taken as soon as remembered unless it is close to the next scheduled dose, in which case the missed dose should be skipped rather than doubled, as advised by a doctor.

Disclaimer

Always use this medicine strictly according to your doctor’s instructions and prescribed dosage.